68Ga FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer

HomeRadiology: Imaging CancerVol. 1, No. 1 PreviousNext Research HighlightsFree Access68Ga FAPI PET/CT: Tracer Uptake in 28 Different Kinds of CancerDeep K. Hathi, Ella F. JonesDeep K. Hathi, Ella F. JonesDeep K. HathiElla F. JonesPublished Online:Sep 27 2019https://doi.org/10.1148/rycan.2019194003MoreSectionsPDF ToolsImage ViewerAdd to favoritesCiteTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinked In Take-Away Points■ Major focus: Assessing the clinical effectiveness of quinolone-based fibroblast-activated protein inhibitors (FAPIs) as PET radiotracers in a range of cancers.■ Key result: Uptake of FAPI is cancer dependent. The low hepatic background and minimal nonspecific uptake may improve the detection of hepatic metastatic lesions and challenging epithelial cancers.■ Impact: FAPI PET/CT may provide a complementary imaging strategy to fluorodeoxyglucose PET/CT in highly inflamed or fibrotic tumors.Fluorodeoxyglucose (FDG) PET/CT is the primary imaging modality for cancer diagnosis, staging, and management. However, in cancers with high background uptake, inflammation, or low metabolic activity, FDG uptake is not as effective at tumor delineation and identifying metastatic lesions. An attractive complementary imaging target is the fibroblast-activated protein (FAP), which is preferentially expressed in cancer-associated fibroblasts. FAP overexpression is linked to increased local inflammation, suppression of lymphocyte activity, and poor prognosis in epithelial cancers. Quinolone-based FAP inhibitors (FAPIs) constitute a new strategy for targeting the tumor stroma and have been adapted as radiopharmaceuticals. However, while preliminary studies have demonstrated preclinical and clinical safety and efficacy, testing in a larger, more diverse clinical setting is required to identify specific applications for FAPI-based tracers. In their article, Kratochwil et al conducted a retrospective analysis of 80 patients, with 28 different epithelial carcinomas, who received a gallium 68–conjugated quinoline-based FAPI tracer (68Ga-FAPI-04). There was differential uptake of 68Ga FAPI based on the carcinoma type, although there was no statistically significant difference between primary and metastatic lesions. Larger cohort sizes and cancer-specific imaging are likely required to highlight any uptake effects between lesions. Highest uptake was seen in sarcomas, breast, esophageal, and salivary gland cancers, while maximum standardized uptake value was low in renal, gastric, and prostate cancers. Interestingly, metastatic liver and lung lesions were highlighted against a low background, which suggests a promising venue for using FAPI PET/CT in metabolically active tissues. These results suggest that FAPI-based PET/CT may provide a complementary imaging strategy to FDG PET/CT for identifying highly fibrotic tumors and metastatic lesions.Highlighted Article Kratochwil C, Flechsig P, Lindner T et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801–805. doi: 10.2967/jnumed.119.227967. [Epub 2019 Apr 6]Highlighted ArticleKratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801–805. doi: 10.2967/jnumed.119.227967. [Epub 2019 Apr 6]. Crossref, Medline, Google ScholarArticle HistoryPublished online: Sept 27 2019 FiguresReferencesRelatedDetailsCited By68Ga-FAPI-04 PET/CT In Primary Signet Ring–Like Cell Carcinoma of Prostate With Bone MetastasesGamzeTatar, SevimBaykal Koca, İsaSevindir, NurhanErgül, Tevfik FikretÇermik2023 | Clinical Nuclear Medicine, Vol. 48, No. 4Fibroblast Activation Protein Inhibitor TheranosticsShobhanaRaju, JayaShukla, RakeshKumar2022 | PET Clinics, Vol. 17, No. 3Fibroblasts, a target for imaging and therapeutics in rheumatoid arthritisGuillermoCarvajal Alegria, Adam PCroft2022 | Rheumatology, Vol. 61, No. 7Comparison of 18F-FDG and 68Ga-FAPI PET/CT in Gastric Kaposi SarcomaGamzeTatar, EdizBeyhan, ÖzgeErol Fenercioğlu, EsraArslan, Tevfik FikretÇermik2022 | Clinical Nuclear Medicine, Vol. 47, No. 9Different Features of 18F-FAPI, 18F-FDG PET/CT and MRI in the Evaluation of Extrahepatic Metastases and Local Recurrent Hepatocellular Carcinoma (HCC): A Case Report and Review of the LiteratureDongheChen, ChengdongChang, YafeiZhang, ShuyeYang, GuolinWang, LiliLin, XinZhao, KuiZhao, XinhuiSu2022 | Cancer Management and Research, Vol. Volume 14Contribution of positron emission tomography/magnetic resonance imaging in musculoskeletal malignanciesLinaGARCÍA CAÑAMAQUE, Caroline A.FIELD, Felipe S.FURTADO, IsabelPLAZA DE LAS HERAS, Jad S.HUSSEINI, ReneBALZA, MohamedJARRAYA, Onofrio A.CATALANO, MercheMITJAVILA CASANOVAS2022 | The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 66, No. 1Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in MiceJasmin M.Klose, JasminWosniack, JanetteIking, MagdalenaStaniszewska, FadiZarrad, MarijaTrajkovic-Arsic, KenHerrmann, Pedro FragosoCosta, KatharinaLueckerath, Wolfgang P.Fendler2022 | Journal of Nuclear Medicine, Vol. 63, No. 9FAPI PET/CT in the Diagnosis of Abdominal and Pelvic TumorsTianshuoYang, LongMa, HaodongHou, FengGao, WeijingTao2022 | Frontiers in Oncology, Vol. 11Application Prospect of Radionuclide Tracer Technology in Clinical Imaging Therapy and Drug DevelopmentQinlinWan2022 | Highlights in Science, Engineering and Technology, Vol. 14Recommended Articles Radiotheranostics in Cancer Diagnosis and ManagementRadiology2018Volume: 286Issue: 2pp. 388-400Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate CancerRadiology2018Volume: 288Issue: 2pp. 495-505Competitive Advantage of PSMA Theranostics in Prostate CancerRadiology2021Volume: 299Issue: 2pp. 261-263Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and PitfallsRadioGraphics2017Volume: 38Issue: 1pp. 200-217Diagnostic Performance of 68Ga Prostate-specific Membrane Antigen PET/MRI Compared with Multiparametric MRI for Detecting Clinically Significant Prostate CancerRadiology2021Volume: 301Issue: 2pp. 379-386See More RSNA Education Exhibits Nuclear Imaging of Prostate Cancer: Old, Present and Future OptionsDigital Posters2020Imaging Spectrum of Prostate Cancer Recurrence and Systemic Metastases: Guidance for DetectionDigital Posters2018Prostate Cancer: What We Already Know About What Is on the HorizonDigital Posters2020 RSNA Case Collection Locally advanced, metastatic prostate adenocarcinomaRSNA Case Collection2020Anterior transition zone prostate adenocarcinomaRSNA Case Collection2020Ewing's sarcomaRSNA Case Collection2020 Vol. 1, No. 1 Metrics Altmetric Score PDF download